Use of poly(amido)amine dendrimers in prevention of early non-enzymatic modifications of biomacromolecules

Biochimie

Volumn 92, Issue 10, 2010, Pages 1296-1305

  Labieniec, Magdalena ^a   Watala, Cezary ^b  

^a UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Hyperglycaemia; Non enzymatic glycosylation (glycation); PAMAM dendrimers; Primary amines; Surface modifications

Indexed keywords

BOVINE SERUM ALBUMIN; DENDRIMER; GLUCOSE; POLYAMIDOAMINE; POLYAMIDOAMINE G2; POLYAMIDOAMINE G4; POLYLYSINE; UNCLASSIFIED DRUG;

ARTICLE; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME MODIFICATION; GLYCATION; MOLECULAR WEIGHT; RADIOMETRY; SPECTROFLUOROMETRY;

ANIMALS; BIOPOLYMERS; DENDRIMERS; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HYPERGLYCEMIA; MOLECULAR WEIGHT; POLYAMINES; POLYLYSINE; SERUM ALBUMIN, BOVINE;

EID: 77957119256     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2010.06.002     Document Type: Article

References (39)

1. Lapolla A., Traldi P., Fedele D. Importance of measuring products of non-enzymatic glycation of proteins. Clin. Biochem. 2005, 38:103-115.
2. Miyata T., Ishikawa N., Van Ypersele D.S. Carbonyl stress and diabetic complications. Clin. Chem. Lab. Med. 2003, 41:1150-1158.
3. Rabbani N., Thornalley P.J. The dicarbonyl proteome: proteins susceptible to dicarbonyl glycation at functional sites in health, aging, and disease. Ann. N.Y. Acad. Sci. 2008, 1126:124-127.
4. Thornalley P.J. Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems-role in ageing and disease. Drug Metabol. Drug Interact. 2008, 23:125-150.
5. Vlassara H., Palace M.R. Glycoxidation: the menace of diabetes and aging. Mt. Sinai J. Med. 2003, 70:232-241.
6. Reddy G.K. Glucose-mediated in vitro glycation modulates biomechanical integrity of the soft tissues but not hard tissues. J. Orthop. Res. 2003, 21:738-743.
7. Rahbar S., Nadler J.L. A new rapid method to detect inhibition of Amadori product generated by delta-gluconolactone. Clin. Chim. Acta 1999, 287:123-130.
8. Labieniec M., Ulicna O., Vancova O., Glowacki R., Sebekova K., Bald E., Gabryelak T., Watala C. PAMAM G4 dendrimers lower high glucose but do not improve reduced survival in diabetic rats. Int. J. Pharm. 2008, 364:142-149.
9. Najlah M., Freeman S., Attwood D., D'Emanuele A. In vitro evaluation of dendrimer prodrugs for oral drug delivery. Int. J. Pharm. 2007, 336:183-190.
10. Heiden T.C., Dengler E., Kao W.J., Heideman W., Peterson R.E. Developmental toxicity of low generation PAMAM dendrimers in zebrafish. Toxicol. Appl. Pharmacol. 2007, 225:70-79.
11. Jevprasesphant R., Penny J., Attwood D., McKeown N.B., D'Emanuele A. Engineering of dendrimer surfaces to enhance transepithelial transport and reduce cytotoxicity. Pharm. Res. 2003, 20:1543-1550.
12. Jevprasesphant R., Penny J., Jalal R., Attwood D., McKeown N.B., D'Emanuele A. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int. J. Pharm. 2003, 252:263-266.
13. Kim Y., Klutz A.M., Jacobson K.A. Systematic investigation of polyamidoamine dendrimers surface-modified with poly(ethylene glycol) for drug delivery applications: synthesis, characterization, and evaluation of cytotoxicity. Bioconjug. Chem. 2008, 19:1660-1672.
14. Kolhatkar R.B., Kitchens K.M., Swaan P.W., Ghandehari H. Surface acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability. Bioconjug. Chem. 2007, 18:2054-2060.
15. El Sayed M., Ginski M., Rhodes C., Ghandehari H. Transepithelial transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers. J. Control Release 2002, 81:355-365.
16. Thoma G., Streiff M.B., Katopodis A.G., Duthaler R.O., Voelcker N.H., Ehrhardt C., Masson C. Non-covalent polyvalent ligands by self-assembly of small glycodendrimers: a novel concept for the inhibition of polyvalent carbohydrate-protein interactions in vitro and in vivo. Chemistry 2005, 12:99-117.
17. Baek M.G., Roy R. Synthesis and protein binding properties of T-antigen containing GlycoPAMAM dendrimers. Bioorg. Med. Chem. 2002, 10:11-17.
18. Tsvetkov D.E., Nifantiev N.E. Dendritic polymers in glycobiology. Russ. Chem. Bull. Int. Ed. 2005, 54:1065-1083.
19. Gabellieri E., Strambini G.B., Shcharbin D., Klajnert B., Bryszewska M. Dendrimer-protein interactions studied by tryptophan room temperature phosphorescence. Biochim. Biophys. Acta 2006, 1764:1750-1756.
20. Klajnert B., Bryszewska M. The interaction of tryptophan and ANS with PAMAM dendrimers. Cell Mol. Biol. Lett. 2002, 7:1087-1094.
21. Klajnert B., Bryszewska M. Fluorescence studies on PAMAM dendrimers interactions with bovine serum albumin. Bioelectrochemistry 2002, 55:33-35.
22. Klajnert B., Stanislawska L., Bryszewska M., Palecz B. Interactions between PAMAM dendrimers and bovine serum albumin. Biochim. Biophys. Acta 2003, 1648:115-126.
23. Shcharbin D., Ottaviani M.F., Cangiotti M., Przybyszewska M., Zaborski M., Bryszewska M. Impact of PAMAM G2 and G6 dendrimers on bovine serum albumin (fatty acids free and loaded with different fatty acids). Colloids Surf. B. Biointerfaces 2008, 63:27-33.
24. Garlick R.L., Mazer J.S. The principal site of nonenzymatic glycosylation of human serum albumin in vivo. J. Biol. Chem. 1983, 258:6142-6146.
25. Iberg N., Fluckiger R. Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites. J. Biol. Chem. 1986, 261:13542-13545.
26. Hilger C., Grigioni F., De Beaufort C., Michel G., Freilinger J., Hentges F. Differential binding of IgG and IgA antibodies to antigenic determinants of bovine serum albumin. Clin. Exp. Immunol. 2001, 123:387-394.
27. Tomalia D.A., Naylor A.M., Goddard I.W.A. Starburst dendrimers: molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter. Angew. Chem. Int. Ed. 1990, 29:138-175.
28. Wang D., Imae T., Miki M. Fluorescence emission from PAMAM and PPI dendrimers. J. Colloid Interface Sci. 2007, 306:222-227.
29. Labieniec M., Przygodzki T., Carsky J., Malinska D., Rysz J., Watala C. Effects of resorcylidene aminoguanidine (RAG) on selected parameters of isolated rat liver mitochondria. Chem. Biol. Interact 2009, 179:280-287.
30. Fréchet J.M.J., Tomalia D.A. Dendrimers and Other Dendritic Polymers 2001, Wiley, Chichester.
31. Gorman C.B., Smith J.C. Effect of repeat unit flexibility on dendrimer conformation as studied by atomistic molecular dynamics simulations. Polymer 2000, 41:675-683.
32. Majoros I.J., Myc A., Thomas T., Mehta C.B., Baker J.R. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules 2006, 7:572-579.
33. Bourdon E., Loreau N., Blache D. Glucose and free radicals impair the antioxidant properties of serum albumin. FASEB J. 1999, 13:233-244.
34. Koizumi K., Ikeda C., Ito M., Suzuki J., Kinoshita T., Yasukawa K., Hanai T. Influence of glycosylation on the drug binding of human serum albumin. Biomed. Chromatogr. 1998, 12:203-210.
35. Nakajou K., Watanabe H., Kragh-Hansen U., Maruyama T., Otagiri M. The effect of glycation on the structure, function and biological fate of human serum albumin as revealed by recombinant mutants. Biochim. Biophys. Acta 2003, 1623:88-97.
36. Shcharbin D., Klajnert B., Bryszewska M. The effect of PAMAM dendrimers on human and bovine serum albumin at different pH and NaCl concentrations. J. Biomater. Sci. Polym. Ed. 2005, 16:1081-1093.
37. Svenson S., Tomalia D.A. Dendrimers in biomedical applications-reflections on the field. Adv. Drug Deliv. Rev. 2005, 57:2106-2129.
38. Criscione J.M., Le B.L., Stern E., Brennan M., Rahner C., Papademetris X., Fahmy T.M. Self-assembly of pH-responsive fluorinated dendrimer-based particulates for drug delivery and noninvasive imaging. Biomaterials 2009, 30:3946-3955.
39. Shcharbin D., Janicka M., Wasiak M., Palecz B., Przybyszewska M., Zaborski M., Bryszewska M. Serum albumins have five sites for binding of cationic dendrimers. Biochim. Biophys. Acta 2007, 1774:946-951.